A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan

INTRODUCTION: Lorlatinib is an ALK tyrosine kinase inhibitor approved in Japan for the treatment of advanced ALK+ NSCLC. There has been little evidence about lorlatinib efficacy after first-line (1L) alectinib in clinical practice in Japan. METHODS: We retrospectively analyzed patients with advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Goto, Yasushi, Kenmotsu, Hirotsugu, Tamiya, Motohiro, Murakami, Shuji, Kurata, Takayasu, Yanagitani, Noriko, Taniguchi, Hirokazu, Kuyama, Shoichi, Shimizu, Junichi, Yokoyama, Toshihide, Shimada, Naoko, Maeda, Tadashi, Tamiya, Akihiro, Uchiyama, Ayumi, Imaizumi, Kazuyoshi, Takahama, Takayuki, Kato, Terufumi, Hayashi, Hidetoshi, Shiraiwa, Naoko, Toyoizumi, Shigeyuki, Kikkawa, Hironori, Thomaidou, Despina, Nishio, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209333/
https://www.ncbi.nlm.nih.gov/pubmed/37250506
http://dx.doi.org/10.1016/j.jtocrr.2023.100508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209333/
https://www.ncbi.nlm.nih.gov/pubmed/37250506
http://dx.doi.org/10.1016/j.jtocrr.2023.100508

Ejemplares similares